一种非常长效的exatecan及其与DNA损伤反应抑制剂的协同作用
Shaun D Fontaine1, Christopher W Carreras1, Ralph R Reid1
1ProLynx, San Francisco, California.
Cancer research communications
|June 28, 2023
概括
一种新型的聚乙烯甘醇 - 埃克萨特干 (PEG-Exa) 结合物显示出强大的抗癌活性和长时间的瘤抑制. 这种结合物与PARP和ATR抑制剂具有显著的协同作用,提供了一个有前途的新疗法策略.
科学领域:
- 在瘤学瘤学.
- 药物运输 药物运输 药物运输
- 药用化学 医学化学
背景情况:
- 埃克萨 (Exa) 是一种强效的拓酶I抑制剂和抗癌剂.
- 埃克萨已被研究为单个药物,宏分子合物和抗体-药物合物有效载荷.
- 之前的配方在向输送和受控释放方面存在局限性.
研究的目的:
- 开发和描述Exa与聚乙烯糖醇 (PEG) 的抗原独立结合物.
- 评估PEG-Exa结合物的药理动力学特征和体内抗癌疗效.
- 评估PEG-Exa与DNA损伤反应抑制剂的协同作用潜力.
主要方法:
- 埃克萨特坎通过β-消除性可切割链接器与4臂40kDa的PEG结合.
- 在小鼠中进行了药理动力学研究,以确定循环半衰期和Exa释放率.
- 在缺乏BRCA1的MX-1异种移植中评估了抗癌疗效,评估了单剂活性和与talazoparib (PARP抑制剂) 和VX970 (ATR抑制剂) 的协同作用.
主要成果:
- 在小鼠中,PEG-Exa结合物表现出12小时的表面循环半衰期.
- 一次低剂量的PEG-Exa可以在40多天内完全抑制瘤生长.
- PEG-Exa与PARP和ATR抑制剂都表现出强烈的协同作用,导致显著的瘤回归和合成致死性.
结论:
- 开发的PEG-Exa合物提供了持续释放的Exa,并显示出强大的,长期的抗癌疗效.
- 抗原独立的PEG-Exa与PARP和ATR抑制剂具有显著的协同作用,突出了其在联合癌症治疗中的潜力.
- 这种结合体代表了开发针对DNA损伤反应通路的新型癌症治疗的有希望的平台.
相关概念视频
Combined Effects of Drugs: Synergism
4.1K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
4.1K
Nucleotide Excision Repair
37.3K
Overview
37.3K
Long-patch Base Excision Repair
7.1K
Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:
7.1K
Base Excision Repair
22.6K
One of the common DNA damages is the chemical alteration of single bases by alkylation, oxidation, or deamination. The altered bases cause mispairing and strand breakage during replication. This type of damage causes minimal change to the DNA double helix structure and can be repaired by the base excision repair (BER) pathways. BER corrects damaged DNA sequences by removing the damaged base and restoring the original base sequence using the complementary strand as a template.
The first step of...
The first step of...
22.6K
DNA Damage can Stall the Cell Cycle
9.2K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.2K
Homologous Recombination
50.7K
The basic reaction of homologous recombination (HR) involves two chromatids that contain DNA sequences sharing a significant stretch of identity. One of these sequences uses a strand from another as a template to synthesize DNA in an enzyme-catalyzed reaction. The final product is a novel amalgamation of the two substrates. To ensure an accurate recombination of sequences, HR is restricted to the S and G2 phases of the cell cycle. At these stages, the DNA has been replicated already and the...
50.7K


